

From backstreet to highstreet

HOW CANNABIS ENTERED
THE MAINSTREAM

THEMATICA INSIGHT REPORT

Contents

About Thematica.....	03
Market overview.....	04
Key facts	05
What does this mean for investors?	06
Survey data.....	07
Table of ASX listed cannabis companies.....	08
Case study - The real-world impacts of changing legislation.....	09
Chapter one - Understanding the players involved in this \$31.96B market.....	10
Company profile - Althea Group	11
Company profile - Little Green Pharma	12
Chapter two - The regulations shaping the industry.....	13
Company profile - Cann Group	14
Company profile - Neurotech International.....	15
Chapter three - The future of cannabis on the ASX	16
Company profile - Elixinol Wellness	17
Case study - Why people want medicinal cannabis	18
Chapter four - Opening the door to other drugs	19
Company profile - Creso Pharma	20
Recap	21
About this report.....	22

ABOUT THEMATICA

See the bigger investment picture

The Market Herald, in conjunction with its digital partners Stockhouse and Advisir, is proud to launch Thematica, a new way for investors to gain insights into global markets.

Self-directed investors make up almost 40% to the total value of the Australian stock market, and they need information to help them make astute investment decisions.

With in-depth research, insightful data and compelling articles, Thematica offers investors the chance to see the bigger picture.

Equally, it represents an opportunity for listed companies to tell their stories and be part of an exclusive global insights series.

Along with Thematica, The Market Herald reaches almost 3 million of the world's most affluent and engaged investors every month.

With an investor database of almost 600,000 subscribers and more than 100 million monthly page impressions, The Market Herald is also one of the world's fastest-growing business and finance platforms.



MARKET OVERVIEW

How cannabis entered the mainstream

After decades of being illegal, cannabis exploded into the mainstream in the late 2010's when it was legalised fully in Canada and partially in Australia.

What followed was a wave of cannabis companies opening up, with many investors happy to inject their money into growing the new market.

Several of those cannabis companies went on to become billion-dollar businesses, however the majority did not. Many stocks struggled with the realisation that creating a pharmaceutical product took time, while others couldn't keep up with the breakneck speed at which they started.

Post COVID-19, the realisation has well and truly set in that cannabis and hemp stocks are not a fad, but a long-term solution to the wider healthcare market.

In Australia, the relationship between the ASX and the cannabis sector is still in its infancy. In other markets though, such as Canada, cannabis is already big business, and the development of this listed sector holds many lessons for Australian investors.

Many of the world's largest cannabis companies are based in Canada, and the country has led the world in legalising the drug for medicinal and recreational use. Despite a recent correction, exacerbated by the pandemic, the Canadian cannabis market holds a

promising future as smaller players merge, and larger companies continue pushing into the US.


While they operate in different environments, all the publicly listed stocks across Canada and Australia are vying for a slice of the rapidly expanding legal cannabis market. This was estimated to be worth \$31.96 billion globally in 2020¹ and it is projected to almost quadruple to \$108.94 billion by 2028.

Beyond profits, there is also a race to transform and approve cannabis and other currently illicit drugs into treatments which can ease suffering.

Some of the people cannabis has been shown to help include veterans who have PTSD, children with Autism Spectrum Disorder (ASD), the elderly with chronic joint pain and the terminally ill who require much-needed pain medication.


While decision-makers may have been slow to support these substances and all they have to offer, business has not been so reluctant.

In this maiden report, Thematica will examine why the future of cannabis lies primarily in healthcare, with investors vying to see the drug transformed into an accessible medical treatment.



Key facts

Australian State & Territory laws



\$31.96 Billion

Estimated value of legal cannabis market in 2020.

Getting higher¹

Legal cannabis market is expected to grow at CAGR of 14.3%

Good to grow²

Amended federal legislation in 2016 gave companies the green light to begin cultivating the drug for scientific and medicinal purposes.

30+

ASX-listed hemp and cannabis stocks

INVESTOR PLAYBOOK

What does this mean for investors?

There are five key learnings investors should keep in mind when examining the cannabis market in Australia.

1. Not all cannabis stocks are actually in cannabis.

There are close to 40 ASX listed stock operating in the cannabis sector, but only around half of all those players are actually immersed in cannabis and hemp cultivation, research or development.

2. Being first means little.

Many companies will state they were the first cannabis stock on the ASX to achieve a specific licence or hit a certain milestone. Though there is a prize for first, it's likely fast followers will beat the first movers.

3. Creating medicinal cannabis products is costly.

Creating a cannabidiol (or CBD, one of the chemical compounds in cannabis) product from start to finish in Australia is a long, time-consuming process which inevitably costs money.

If a business doesn't manage its finances well, it risks never hitting the finish line.

4. Avoid cannabis and hemp products which are gimmicks.


Better health and wellness is a growing desire for many, however some companies may try to jump on this trend to make a quick buck. While cannabis and hemp have proven health benefits, not every product needs to be infused with them.

5. The future of cannabis lies in the pharmaceutical and healthcare sectors.


Not the recreational market. In North America the opposite is true, but examining the Australian Government's legislation around cannabis reveals little desire to make the drug legal for recreational use.

What investors told us

A survey of more than 100 investors by Thematica revealed a number of key insights into the “future of alternative medicines”.



Growth sectors



67.72%

Likely to use these products and treatments in

Investors feel **regulatory developments**



are **most likely** to drive this sector over the next 12 months


Gender

87% male




13% female

Employment



Income



Ticker code	Company name	Last close price [†]	SOI	MCap at last close [†]	Mcap at last close (\$M)
IHL	Incannex Healthcare Ltd	\$0.275	1,060,332,760.00	\$291,591,509	\$291.59
EOF	Ecofibre Ltd	\$0.800	341,015,977.00	\$272,812,782	\$272.81
CPH	Creso Pharma Ltd	\$0.130	1,148,417,635.00	\$149,294,293	\$149.29
CAN	Cann Group Ltd	\$0.380	277,911,998.00	\$105,606,559	\$105.60
MXC	MGC Pharmaceuticals Ltd	\$0.041	2,334,751,049.00	\$95,724,793	\$95.72
LGP	Little Green Pharma Ltd	\$0.850	178,573,245.00	\$151,787,258	\$151.78
AGH	Althea Group Holdings Ltd	\$0.325	262,373,540.00	\$85,271,401	\$85.27
IDT	IDT Australia Ltd	\$0.350	239,860,170.00	\$83,951,060	\$83.95
BOT	Botanix Pharmaceuticals Ltd	\$0.078	973,142,074.00	\$75,905,082	\$75.90
MDC	Medlab Clinical Ltd	\$0.160	342,175,671.00	\$54,748,107	\$54.74
ZLD	Zelira Therapeutics Ltd	\$0.049	1,190,322,966.00	\$58,325,825	\$58.32
AC8	Auscann Group Holdings Ltd	\$0.105	440,547,110.00	\$46,257,447	\$46.25
EXL	Elixinol Wellness Ltd	\$0.120	315,063,154.00	\$37,807,578	\$37.80
BDA	Bod Australia Ltd	\$0.340	105,823,920.00	\$35,980,133	\$35.98
NTI	Neurotech International Ltd	\$0.056	686,819,126.00	\$39,021,871	\$39.02
APH	Australian Primary Hemp Limited	\$0.385	76,410,135.00	\$29,417,902	\$29.41
CGB	Cann Global Ltd	\$0.006	5,139,255,284.00	\$30,835,532	\$30.83
EPN	Epsilon Healthcare Ltd	\$0.140	192,706,949.00	\$26,978,973	\$26.97
ECS	ECS Botanics Holding Ltd	\$0.041	635,919,237.00	\$26,072,689	\$26.07
MMJ	MMJ Group Holdings Limited	\$0.087	229,953,985.00	\$20,005,997	\$20.00
SCU	Stemcell United Ltd	\$0.020	1,043,320,658.00	\$20,866,413	\$20.86
ESE*	Esense-Lab Ltd	\$0.018	510,038,022.00	\$9,180,684	\$9.18
LV1	Live Verdure Ltd	\$0.235	40,027,251.00	\$9,406,404	\$9.40
MRG	Murray River Organics Group Limited	\$0.190	44,115,143.00	\$8,381,877	\$8.38
CAU	Cronos Australia Ltd	\$0.115	48,625,000.00	\$5,591,875	\$5.59

*suspended since 22/07/20 †21.7.21

CASE STUDY

Josie, 49*

A car accident at aged 20 left Josie with intense chronic pain and nerve damage. After failing to find relief in opiates, she found herself turning to cannabis oil.

The medicine helped immensely and Josie became a lifelong advocate, helping others access the cannabis her country deemed illegal.


This advocacy led to her drug arrest in 2017, but Josie still recommends the drug for who can't find relief.

"I didn't have any other choice and that's why I helped others," Josie said.

"There's still a lot of people who can't access it for different reasons, whether they can't get a prescription or they just can't afford it.

"Until that's addressed, we're still going to have people accessing the black market and making it themselves and risking going to jail."

*Not her real name.



There's still a lot of people who can't access it for different reasons, whether they can't get a prescription or they just can't afford it.

CHAPTER ONE

Understanding the players involved in this \$31.96B market

Cannabis companies in Australia have taken great strides in progressing the nation's attitudes towards the medicinal use of the drug. While the drug remains strictly controlled, there have been notable advances in the size and scope of Australia's cannabis market.

The first cannabis company was listed on the ASX in 2015. Less than six years later there are close to 40 cannabis and hemp businesses listed on the ASX. The growth isn't limited only to the list of companies in the market, the number of reported patients using medicinal cannabis has also steadily increased over the years.

Australia's medicines watchdog announced in December 2020 that it would allow selected products with cannabidiol to be sold in pharmacies in the next year. Given how recently this decision was made, it appears that there is still considerable room for growth among Australian cannabis players.

COMPANY PROFILE

Althea Group

TICKER	CHIEF EXECUTIVE OFFICER	SHARE PRICE	MARKET CAP
ASX: AGH /	JOSH FEGAN /	\$0.33* /	\$85.27M*

*as of 21 July, 2021

Althea Group (AGH) is an ASX-listed stock which operates multiple cannabis businesses across the globe, giving it access to a substantial market.

At the core of the business is the self-titled company Althea, which produces medicinal cannabis products available only by prescription.

AGH’s other business is Peak Processing Solutions, which operates in the Canadian recreational cannabis market.

Additionally, AGH has created a free online education portal for GPs and other healthcare professionals. The accredited course allows participants to learn about the efficacy and safety of medicinal cannabis treatments.

The education component of the business is important, as the company’s products are available only in legal markets such as the UK, Germany, Australia and Canada.

AGH has begun eyeing other countries, and CEO Josh Fegan said the group wants to expand into other European and North American markets.

However the company’s expansion would partially depend on various governments relaxing their cannabis laws.

“Peak’s operations are limited to Canada at the moment,” Mr Fegan said.

“However, there is hope the US and Mexico will also legalise recreational cannabis in the coming months and years, with many other First World countries expected to follow.”

Along with entering other countries once laws change, AGH also wants to establish itself as a market leader in both the medicinal and recreational markets.


Mr Fegan said he sees AGH following in the footsteps of British pharmaceutical company, GW Pharmaceuticals, which pioneered the first market-approved cannabis treatment.

“Althea has been touted as the next GW Pharma and has a very solid strategy to see its products distributed throughout the world,” Mr Fegan said.

“There is hope the US and Mexico will also legalise recreational cannabis in the coming months and years, with many other first world countries expected to follow.”

JOSH FEGAN
Althea Group CEO

ASX:AGH



COMPANY PROFILE

Little Green Pharma

TICKER	MANAGING DIRECTOR	SHARE PRICE	MARKET CAP
ASX:LGP	FLETA SOLOMON	\$0.85*	\$151.78M*

*as of 21 July, 2021

Little Green Pharma (LGP) entered the market back in 2016 with a clear focus on patients and a goal to create better pharmaceutical grade cannabis treatments.

Now, with its vertically integrated supply chain, the business has managed to achieve just that.

For close to three years LGP has been offering Australia’s first locally made cannabis medicines, including a range of CBD and THC blended oils and dried flowers, to Australians through the Special Access Scheme.

LGP’s focus on patients has also led to the company becoming the first cannabis stock in Australia to team up with a health fund to lower the cost of its medicines.

Its partnership with HIF, announced last November, was a milestone for the business.

“LGP’s focus is on pharmaceutical-grade cannabis used for treating medical conditions,” Managing Director Fleta Solomon said.

“This is fundamental as our purpose is to do extraordinary things for our patients and transform lives around the world using our Australian cannabis medicines.”

In addition to the Australian insurance partnership, LGP has set its sights on helping patients abroad, with the company beginning exports of its home-grown products to European countries including Germany and France.

To keep up with demand, LGP has begun significantly expanding its cultivation and manufacturing capacity.

Commenting on the company’s future, LGP’s leader said she expects the business to grow

alongside the drug’s recognition among the medical community.

“Essentially, we’re getting closer to a point where cannabis is being recognised as just another medicine in the doctor’s toolbox and it is far more accessible for patients who need it,” Ms Solomon said.

“Although we’re seeing thousands of GPs nationally now prescribing, the pace and scale of the introduction of medicinal cannabis is unprecedented and this has raised challenges for health professionals, with many still requesting further evidence of its benefits.”

To support further research, LGP announced in February it will supply its cannabis to a wide-ranging study examining quality of life outcomes in patients who have been prescribed the medicines.


The QUEST Initiative study is being carried out by the University of Sydney, while LGP is responsible for the cultivation and supplies.

“We’re getting closer to a point where cannabis is being recognised as just another medicine in the doctor’s toolbox and it is far more accessible for patients who need it.”

FLETA SOLOMON

Little Green Pharma Managing Director

ASX:LGP



CHAPTER TWO

The regulations shaping the industry

In a monumental shift for the Australian cannabis industry, amended legislation in 2016 gave companies the green light to begin cultivating the drug in Australia for medicinal and scientific purposes.

In the five short years that have followed, even more legislative advances have been made, opening the industry up to domestic and regional patients.

Despite this progress, Australia's regulation of medicinal cannabis continues to be extremely strict, with the Therapeutic Goods Association (TGA) and Office of Drug Control (ODC) both overseeing the industry.

The TGA in particular has spent a lot of time reviewing the efficacy of the drug and announced late last year plans to 'down schedule' CBD. This essentially makes it possible for low doses of the drug to be sold in pharmacies.

Medicines that fail to meet these criteria are still accessible by the Special Access Scheme, with more than 116,000 applications approved so far, according to TGA's figures³.

Additionally, the ODC gave the green light to cannabis exports in early 2018. It was a fateful decision for some companies, as it opened up profitable new revenue streams as they began sending their well-regulated products overseas.

COMPANY PROFILE

Cann Group

TICKER	CHIEF EXECUTIVE OFFICER	SHARE PRICE	MARKET CAP
ASX:CAN	PETER CROCK	\$0.38*	\$105.6M*

*as of 21 July, 2021

Cann Group (CAN) describes itself as a leader within the Australian cannabis industry, having distinguished itself back in 2016 as the first company to receive an ODC licence.

The licence allowed it to begin cultivating the drug, which the company now supplies to other cannabis companies.

Fulfilling a B2B role within the industry appealed to CAN as it allowed the business to avoid the time and cost involved in developing products for patients.

CEO Peter Crock said Australia’s cannabis product regulations were some of the most rigorous in the world.

“It’s something we have had to work through,” Mr Crock said.

“As the first (ODC) licence holder we’ve led the way, which has been hard work, but positive.”

Along with heading up CAN, Mr Crock also leads Medicinal Cannabis Industry Australia, the peak national body representing growers and scientists.

He argues strict regulations were exactly what makes Australian cannabidiol products the best in the world.

“The products made here are going to be world leading as the restrictions are so tight,” Mr Crock said.

“It also means Australian patients are accessing the best medicinal cannabis in the world.”

Moving forward, CAN hopes to have its Mildura manufacturing facility up and running by the end of the year.

This will give the company access to around 12,500 kilograms of medicinal cannabis dry flower annually.

The company has also announced plans to acquire Satipharm, a European business exclusively licensed to develop and market a proprietary delivery system for cannabinoids.

Additionally, CAN recently celebrated sending Australia’s largest export of cannabis to Germany.


It believes this region could prove to be profitable as it has similarly stringent regulations surrounding the drug as Australia.

“The German opportunity is not easy to get into, but Australia’s legislation has set us up well to play in that space,” Mr Crock said.

“The products made here are going to be world leading as the restrictions are so tight.”

PETER CROCK
Cann Group CEO

ASX:CAN



COMPANY PROFILE

Neurotech International

TICKER	NON-EXECUTIVE CHAIRMAN	SHARE PRICE	MARKET CAP
ASX:NTI	BRIAN LEEDMAN	\$0.056*	\$39.02M*

*as of 21 July, 2021

Neurotech International (NTI) is a medical device and solutions business which entered the world of cannabis through its own novel strains of the drug.

Its propriety DOLCE/NTI strains have been proven to reduce inflammation within brain cells, as well as producing a number of other beneficial effects.

Building on this recent success, NTI has begun testing its cannabis strains on children with Autism Spectrum Disorder (ASD) as part of a clinical study at Monash Children’s Hospital in Victoria.

Helping those with ASD is a primary focus for NTI, which has created a neurotherapy feedback device called Mente that helps those on the autism spectrum self-regulate attention and mood.

Explaining the focus of the DOCLE/NTI study, Non-Executive Chairman Brian Leedman said the company wants to see how safe and effective its cannabis strains were as a treatment for ASD.

“This is the first time that full-spectrum, with less than 0.3% THC medicinal cannabis strains, will be assessed in (children with) ASD,” Mr Leedman said.

“Safety is a primary concern and the study should be relatively low risk as cannabis is generally considered to be safe.

“Efficacy is a secondary outcome and positive change in children’s behaviours will be proof positive of the neurological effects of our cannabis strains.”

Alongside the clinical study, NTI has begun discussions with the TGA about registering its novel

strains of cannabidiol as well as potential therapeutic expansion.

The company believes Australia is only now beginning to discover the true potential of cannabis and it has committed to work alongside regulatory bodies to conduct appropriate research examining the drug’s uses.

“The cannabis sector is an exciting one as research into the medicinal benefits of cannabis has only taken place in recent years despite its use throughout recorded history,” Mr Leedman said.


“I have no doubt that CBD is the key to effective treatment of neurological disorders.

“But the ability to produce natural cannabis strains with full spectrum CBD and little to no THC is unique to Neurotech, and this presents a tremendous market opportunity.”

“I believe that the demand for cannabis medicines is for a completely natural product and only Neurotech has the potential to develop a product to meet that huge market need.”

BRIAN LEEDMAN
Neurotech International Non-Executive Chairman

ASX:NTI



CHAPTER THREE

The future of cannabis on the ASX

The scientific evidence is becoming clearer that cannabis can help treat illnesses and disorders in both humans and animals.

However, the time and cost involved in researching, developing and then getting a cannabis product approved for use in Australia is both lengthy and expensive. In the meantime, cannabis companies are increasingly being snapped up by fellow players or larger healthcare stocks swooping in on opportunities.

One example of this is AusCann, the ASX-lister which bought out CannPal and merged the two businesses' research for a better chance of long-term success. More conservative health stalwarts have also been turning their attention to cannabis, as seen by the number of US patents already issued to pharmaceutical giant Pfizer — at least 14 and counting⁴.

It's not just healthcare giants that want to take cannabis into the mainstream. Large alcohol or tobacco companies have also begun buying up smaller American cannabis players. For example, the owner of Bud Light, AB InBev, sunk US\$50 million into a joint venture with cannabis company Tilray to look into infusing drinks with the substance.

Given the expenses involved in launching CBD products as well as the wider interest from larger stocks, it appears the future of cannabis lies at least partly in the mergers and acquisitions (M+A) game.

COMPANY PROFILE

Elixinol Wellness

TICKER CHIEF EXECUTIVE OFFICER SHARE PRICE MARKET CAP

ASX:EXL OTCQB:ELLXF / OLIVER HORN / \$0.12* / \$37.8M*

*as of 21 July, 2021

The ASX listed Elixinol Wellness (EXL) may have recently changed its name, but the company is quick to stress it’s not just some wellness fad.

Instead, Elixinol describes itself as a heritage hemp company with roots that date back more than 25 years.

“We are not opportunistic new market entrants but are pioneers and have a long heritage in the hemp industry,” Global CEO Oliver Horn said.

The company, once known as Elixinol Global, not only has a long history in the cannabis sector, it’s also arguably one of the more varied cannabis stocks on the ASX.

It operates two core branded product ranges — Elixinol and Hemp Foods Australia.

Elixinol is a global brand which offers a wide range of hemp derived CBD based nutraceutical products in the form of oils, gummies, topical treatments and capsules.

Hemp Foods Australia produces a range of food products including seeds, proteins, flour, oils, bread, spreads and vitamins, as well as a skincare range — all produced from hemp.

Over the years, EXL has established a reach into Australian, European, US, UK, Japanese and South African markets.

Additionally, EXL’s commitment to being a long-term player has led to the company entering the M+A game and consider acquiring an EU-based cannabis businesses.

Looking ahead, the company’s leader was confident that other regions in Europe and other parts of the world would prove profitable as regulations relax and the focus on wellness grows.

“We are now well positioned across global markets and I believe that all geographies provide significant long-term opportunities for the business,” Mr Horn said.


“The short-term will be impacted by positive regulatory change, a gradual recovery from COVID-19 restrictions and an industry consolidation in the more mature CBD markets.

“All of these dynamics will favour the more established, diversified, compliant and financially sound players like Elixinol Wellness.”

“We are now well positioned across global markets and I believe that all geographies provide significant long-term opportunities for the business.”

OLIVER HORN
Elixinol Wellness CEO

ASX:EXL



CASE STUDY

Matt, 60*

As a former police officer, Matt spent much of his working career trying to stop the illicit drug trade.

Now, he's a leading advocate for the use of medicinal cannabis in those suffering from PTSD.


Matt became familiar with the drug after his own son, a former army member, was diagnosed with the illness.

He explains his boy turned to cannabis after having a bad experience using benzodiazepines, a common treatment for PTSD.

"He was a dribbling basket case, capable of not much more than sleeping all day," Matt said.

"The minute we used cannabis, non-medical cannabis, he no longer needed benzos and got off them that day."

*Not his real name.



□□ **The minute we used cannabis, non-medical cannabis, he no longer needed benzos and got off them from that day.**

CHAPTER FOUR

Opening the door to other drugs

One of the positive side effects of cannabis being recognised as a legitimate treatment for a range of issues is that it has opened the door for other drugs to enter the world of mainstream medicine.

Among the different drugs being reviewed is psilocybin — the active ingredient in magic mushrooms. This drug, as well as other psychedelics, is following in the footsteps of cannabis and being trialled in patients with illnesses that currently don't have a promising treatment.

Initial research has already begun showing promising results, while the global psilocybin market is also gaining strength. A recent report estimated the market will eventually be worth \$14.31 billion by 2027⁵.

Several ASX stocks have already begun to take notice of the promise and made their move into the growing world of psychedelics.

COMPANY PROFILE

Creso Pharma

TICKER	DIRECTOR & CO-FOUNDER	SHARE PRICE	MARKET CAP
ASX:CPH	BOAZ WACHTEL	\$0.13*	\$149.29M*

*as of 21 July, 2021

Creso Pharma (CPH) entered the ASX back in 2017 and since then has launched a range of products for both humans and animals, including therapeutic, nutraceutical and cosmetic products.

The healthcare stock and its reach are as varied as its product range, with multiple cannabis businesses set up across Australia, Canada and Switzerland.

However in a monumental shift for the CPH, it recently announced it would be merging with Canadian recreational psychedelics business Red Light Holland.

The two businesses will merge and launch a new company called The HighBrid Lab on the Canadian Stock Exchange, giving shareholders instant access to the lucrative North American cannabis and psychedelics markets.

Even before the merger, CPH had been in the process of moving into the psychedelics space. It announced earlier this year a plan to acquire Canadian psychedelics treatment company, Halucenex, which is researching the possible treatments options using psilocybin

CPH said the drug was gaining acceptance in the mental health industry, with a recent study by eminent American university Johns Hopkins finding psilocybin mixed with traditional therapy produced positive results in adults with depression⁶.

CPH Non-Executive Chairman and Co-Founder Adam Blumenthal said given the encouraging results, the company was excited to be moving into this potentially life-changing drug market.

“Mental health and PTSD are becoming detrimental to our society and this has been highlighted in the past 12 months,” Mr Blumenthal said.


“Psychedelic-assisted therapy is a new alternative treatment route, which has considerable promise.”

Additionally, Halucenex has flagged plans to carry out research and development work on other psychedelic sub-stances such as LSD, ketamine and MDMA.

While Red Light Holland has the advantage of being well established in the EU, where it sells its unique magic truffles to the legal recreational market in the Netherlands.

“There are a number of synergies across the businesses, which will allow the combined company to considerably scale up operations in the near term,” Mr Blumenthal said.

ASX:CPH



“Psychedelic-assisted therapy is a new alternative treatment route, which has considerable promise.”

ADAM BLUMENTHAL

Creso Pharma Non-Executive Chairman & Co-Founder

RECAP

The road ahead

Investors already in the cannabis sector, or those looking to enter the market would do well to remember how long it takes for medicinal CBD products to come to fruition in Australia. The future of cannabis lies in the healthcare space, but players still need money and patience to get through the years-long development pipeline.

Promisingly, psychedelics are following in the footsteps of cannabis. Fungi, LSD, MDMA and other similar drugs are all the subject of research, with a recent study finding psilocybin had a positive effect when used alongside therapy in those with depression.

Investors across the globe are looking at cannabis and other frontier treatments as a key part of the future of healthcare. The sector has truly emerged from the back street to the high street. And the greatest growth is yet to come.

ABOUT THIS REPORT

The authors



BELINDA CAMERON
Editor, The Market Herald



JOCELYN ASPA
Writer, The Market Herald

Sources

¹<https://www.grandviewresearch.com/industry-analysis/legal-marijuana-market>

²<https://www.listcorp.com/search?q=cannabis>

³<https://www.tga.gov.au/medicinal-cannabis-role-tga>

⁴<https://www.globenewswire.com/news-release/2018/08/15/1552656/0/en/Big-Pharma-Collects-Most-Canadian-Cannabis-Patents.html>

⁵<https://www.globenewswire.com/en/news-release/2021/03/18/2195240/28124/en/Global-Psychedelic-Drugs-Market-Report-2020-Market-Size-is-Projected-to-Reach-10-75-Billion-by-2027.html>


⁶<https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows>

Thanks

With thanks to our sponsors Neurotech International, Little Green Pharma and Creso Pharma.

Disclaimer

The information in this document is intended to be general in nature and is not personal financial product advice and some contents are provided by companies who have paid to be featured in this document. It does not take into account your objectives, financial situation or needs. Before acting on any information, you should consider the appropriateness of the information provided and the nature of the relevant financial product having regard to your objectives, financial situation and needs. In particular, you should seek independent financial advice and read the relevant product disclosure statement (PDS) or other offer document prior to making an investment decision in relation to a financial product (including a decision about whether to acquire or continue to hold).



thematica@themarketherald.com.au



themarketherald.com.au

Australia

Level 11, 28 The Esplanade,
Perth WA 6000

PO Box Z5558, St Georges Tce,
Perth WA

Canada

1185 West Georgia Street,
Suite 1625
Vancouver, British Columbia

Canada V6E 4E6